Irradiation and choroidal melanoma SIR, In their paper questioning whether irradiation is a justifiable treatment for choroidal melanomas Manschot and van Strik' base their conclusions on a thesis that has some major internal inconsistencies. They claim that dissemination of choroidal melanoma generally occurs after the tumour has grown to 7 mm or larger, that doubling times of uveal melanomas vary from 30 to 365 days, that death from metastasis occurs 30-40 doubling times after dissemination, and that tumour related deaths within three years after therapy are caused by pre-existing metastases. This is a reiteration of the views expounded a few years earlier by Manschot and van Peperzeel.2 In his Bowman lecture of 1980 Zimmerman pointed out why those concepts could not be logically used to advocate the need for early enucleation.3 Using their own views concerning the similarly slow growth rates of the primary and metastatic tumours and their own postulates, formulas, and tumour doubling times, some calculations were made and published as Table II Paragraph 3 ('Let us ... Table 1 '): Our model should be 'obviously clearly non-applicable, because ... deaths from metastases are rare when tumours are treated before they have grown larger than 7 mm'. There is no acknowledgment that one of us (WAM) was the first to emphasisel 10 the critical importance of tumour size in small melanomas in prognosis. Analysis of two reports" 12 on the survival of patients with small enucleated melanomas in the <7 mm and the <10 mm diameter groups revealed that the tumour death rate in the two studies of 7-10 mm tumours was about 35% and 40% compared with nil % in the <7 mm groups. The authors of these two reports" 12 calculated 22-7% and 14-3% in the <10 mm groups, because they had not specially determined the death rates in the 7-<10 mm groups. Our model is, contrary to the opinion of Zimmerman et al., fully applicable to the high tumourrelated death rates in the 7-< 10 mm group, because only a very small percentage of melanomas are enucleated before they have grown larger than 7 mm and because calculated doubling times of 36 out of 39 uveal melanomas 6 13" appeared to vary from 60 to 540 days' or even 900 days. by enucleation were compared with those of 21 patients who had been treated with cobalt-60 episcleral plaques in the same period. Of the enucleated patients 22% had died from metastases against 57% of the irradiated patients. The median survival after enucleation was 10 years; after irradiation it was 3-8 years. No other clinics have published the survival figures for all the treated cases for a follow-up period of 10 years or more. We are apprehensive that the ophthalmological community will have to wait for a long time before definitive 10-year survival statistics for all patients treated by irradiation are made available by the majority of the radio-oncology clinics. A collection of anonymous, non-specified cases, as mentioned in the last sentence of the letter by Zimmerman 
